All Stories

  1. When brain networks crash: connectivity, slow-wave activity and neural replay in Alzheimer's disease
  2. Repeated clinical trial failures in Alzheimer’s disease: The pitfalls of pursuing epidemiological associations
  3. CHF6467 Exerts Neuroprotective Effects in the Rat Model of Acute Ischemic Stroke
  4. Reply: The disconnectome as target in Alzheimer disease: a promising framework or a premature end-point?
  5. [18F]-florzolotau PET imaging in Alzheimer's disease: Current evidence and future directions
  6. Physical Exercise and Gut Microbiota: Implications for Alzheimer’s Disease in Experimental Models: A Systematic Review and Meta-Analysis
  7. Revisiting the cognitive potential of lithium in alzheimer’s disease: the role of cholinergic system and brain connectivity
  8. Frailty as an underrepresented dimension in clinical trials of Alzheimer's disease therapies
  9. Long-term treatment of early Alzheimer’s disease with donanemab
  10. Tau Phosphorylation as an Adaptive Physiological Response: Implications for the Therapy of Tauopathies
  11. Developmental brain programmes and biomarker activation in Alzheimer’s disease
  12. Comparing clinical effect sizes of Souvenaid TM , lecanemab, and donanemab in early Alzheimer’s disease
  13. Brain connectivity as a new target for Alzheimer’s disease therapy?
  14. Modeling Alzheimer’s disease through the integration of exposome, inflammasome, and connectome
  15. Physical activity and reduced risk of Alzheimer's disease: potential role of soluble amyloid‐β42
  16. Enhancing uptake of antidiabetic drugs to reduce cardiometabolic risk and dementia burden
  17. Does p-tau217 play a physiological reparative role in neonates and neurodegenerative diseases?
  18. Restoring amyloid-β42 and γ-secretase function in Alzheimer’s disease
  19. Targeting dementia prevention with semaglutide: The case for APOE4 homozygotes
  20. Beyond diabetes: Testing long‐term metformin adherence for dementia prevention
  21. Secretase inhibition in Alzheimer’s therapeutics reveals functional roles of amyloid-beta42
  22. Making a diagnosis of Alzheimer’s disease in asymptomatic individuals with positive biomarkers
  23. CSF amyloid-β40 levels are not associated with efficacy outcomes in Alzheimer’s disease trials
  24. Association between amyloid-β42 levels and neuropsychiatric symptoms in Alzheimer’s disease trials
  25. Can brain network connectivity facilitate the clinical development of disease-modifying anti-Alzheimer drugs?
  26. Microglia-mediated neuroimmune suppression in posttraumatic stress disorder
  27. Metformin may reduce Alzheimer’s disease risk by increasing soluble amyloid-β42 levels
  28. Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials
  29. Are we close to using Alzheimer blood biomarkers in clinical practice?
  30. Transferrin-Conjugated Melittin-Loaded L-Arginine-Coated Iron Oxide Nanoparticles for Mitigating Beta-Amyloid Pathology of the 5XFAD Mouse Brain
  31. Plasma ATN(I) classification and precision pharmacology in Alzheimer's disease
  32. Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story
  33. Different Sides of Depression in the Elderly: An In-depth View on the Role of Aβ Peptides
  34. Should we lower or raise levels of amyloid-β in the brains of Alzheimer patients?
  35. Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?
  36. Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study
  37. Editorial: Neurotrophins Biodelivery to CNS: Innovative Approaches for Disease-Modifying Therapy
  38. Molecular mechanisms of skin wound healing in non-diabetic and diabetic mice in excision and pressure experimental wounds
  39. Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
  40. What have we learned from past failures of investigational drugs for Alzheimer’s disease?
  41. Can platelet activation result in increased plasma Aβ levels and contribute to the pathogenesis of Alzheimer’s disease?
  42. A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies
  43. Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression
  44. Brain Amyloid Deposition in Late-Life Depression
  45. The β-Secretase BACE1 in Alzheimer’s Disease
  46. Accelerating Alzheimer’s disease drug discovery and development: what’s the way forward?
  47. Can Anti–β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?
  48. MiRNA-15b and miRNA-125b are associated with regional Aβ-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints
  49. Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers
  50. Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study
  51. Effects of Topical Application of CHF6467, a Mutated Form of Human Nerve Growth Factor, on Skin Wound Healing in Diabetic Mice
  52. Impairment of the cholinergic anti-inflammatory pathway in older subjects with severe COVID-19
  53. Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism
  54. Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
  55. Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer’s disease or should they be looking elsewhere?
  56. A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
  57. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
  58. Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging
  59. Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease?
  60. Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients?
  61. Structure-activity relationships of flurbiprofen analogues as stabilizers of the amyloidogenic protein transthyretin
  62. Investigational BACE inhibitors for the treatment of Alzheimer’s disease
  63. Time to test antibacterial therapy in Alzheimer’s disease
  64. Drug-induced reductions in brain amyloid-β levels may adversely affect cognition and behavior by a disruption of functional connectivity homeostasis
  65. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?
  66. Disease-modifying therapies for tauopathies: agents in the pipeline
  67. Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs
  68. Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?
  69. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
  70. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?
  71. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease
  72. Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study
  73. Amyloid deposition in a mouse model humanized at the transthyretin and retinol-binding protein 4 loci
  74. The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset
  75. Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer’s Disease and Late-Life Cognitive Disorders: A Systematic Review
  76. Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline
  77. Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation
  78. CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects
  79. Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging
  80. Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association
  81. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
  82. Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy
  83. Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium
  84. Tau aggregation inhibitors: the future of Alzheimer’s pharmacotherapy?
  85. Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?
  86. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease
  87. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease
  88. Coffee Consumption Habits and the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging
  89. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid
  90. Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanisms
  91. CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci
  92. Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
  93. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return?
  94. Pharmacological targeting of the β-amyloid precursor protein intracellular domain
  95. CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice
  96. Is there still any hope for amyloid-based immunotherapy for Alzheimerʼs disease?
  97. Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia
  98. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
  99. CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study
  100. Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors
  101. Receptor for Advanced Glycation End Products Contributes to Postnatal Pulmonary Development and Adult Lung Maintenance Program in Mice
  102. CHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in pre-plaque Tg2576 mice
  103. Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy Subjects
  104. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice
  105. γ-Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease?
  106. Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging
  107. Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer’s disease patients
  108. Metabolic-Cognitive Syndrome: Metabolic Approach for the Management of Alzheimer's Disease Risk
  109. Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective?
  110. Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies
  111. Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
  112. Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie
  113. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging
  114. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease
  115. Interacting with γSecretase for Treating Alzheimer's Disease: From Inhibition to Modulation
  116. Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab
  117. Metabolic Syndrome, Mild Cognitive Impairment and Dementia
  118. Mediterranean Diet in Predementia and Dementia Syndromes
  119. γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
  120. The γ-Secretase Modulator CHF5074 Restores Memory and Hippocampal Synaptic Plasticity in Plaque-Free Tg2576 Mice
  121. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads
  122. Diet and Alzheimer’s disease risk factors or prevention: the current evidence
  123. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?
  124. Gerontechnology for Demented Patients: Smart Homes for Smart Aging
  125. Aluminium in the Diet, Cognitive Decline and Dementia
  126. The γ-Secretase Modulator CHF5074 Reduces the Accumulation of Native Hyperphosphorylated Tau in a Transgenic Mouse Model of Alzheimer’s Disease
  127. Polymorphisms in GlutathioneS-Transferase Omega-1 Gene and Increased Risk of Sporadic Alzheimer Disease
  128. Nutraceutical Properties of Mediterranean Diet and Cognitive Decline: Possible Underlying Mechanisms
  129. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease
  130. Are γ-secretase inhibitors detrimental for Alzheimer's disease patients?
  131. Peripheral Antioxidant Markers in Mild Cognitive Impairment and its Progression to Dementia
  132. Metabolic Syndrome and Cognitive Impairment: Current Epidemiology and Possible Underlying Mechanisms
  133. Dietary Unsaturated Fatty Acids and Risk of Mild Cognitive Impairment
  134. Is Insulin Resistant Brain State a Central Feature of the Metabolic-Cognitive Syndrome?
  135. Comparison of Pharmacological Modulation of APP Metabolism in Primary Chicken Telencephalic Neurons and in a Human Neuroglioma Cell Line
  136. REVIEW: γ‐Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State
  137. Aluminum in the Diet and Alzheimer's Disease: From Current Epidemiology to Possible Disease-Modifying Treatment
  138. CHF5074, a Novel γ-Secretase Modulator, Restores Hippocampal Neurogenesis Potential and Reverses Contextual Memory Deficit in a Transgenic Mouse Model of Alzheimer's Disease
  139. Interleukin 6–174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease
  140. Late-Life Depression, Mild Cognitive Impairment, and Dementia: Possible Continuum?
  141. Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid
  142. Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment?
  143. Beyond the neurotransmitter-focused approach in treating Alzheimer’s Disease: drugs targeting β-amyloid and tau protein
  144. Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists
  145. Why Did Tarenflurbil Fail in Alzheimer's Disease?
  146. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease
  147. Disease-Modifying Approach to the Treatment of Alzheimerʼs Disease
  148. CHF5074, a novel γ-secretase modulator, attenuates brain β-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease
  149. Polyunsaturated Fatty Acid and S-Adenosylmethionine Supplementation in Predementia Syndromes and Alzheimer's Disease: A Review
  150. Alzheimer's disease: γ-secretase inhibitors
  151. Editorial [Hot Topic:Gamma-Secretase Inhibitors and Modulators as a Therapeutic Approach to Alzheimers disease (Guest Editor: Bruno P. Imbimbo)]
  152. Therapeutic Potential of γ -Secretase Inhibitors and Modulators
  153. 1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel γ-Secretase Modulator, Reduces Brain β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity
  154. Discovery of Diaryl Imidazolidin-2-one Derivatives, a Novel Class of Muscarinic M3 Selective Antagonists (Part 1)
  155. In vitro and in vivo profiling of CHF5022 and CHF5074
  156. Discovery of Diaryl Imidazolidin-2-one Derivatives, a Novel Class of Muscarinic M3 Selective Antagonists (Part 2)
  157. Conformation-sensitive Antibodies against Alzheimer Amyloid-β by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide
  158. CHF3381, a N-methyl-D-aspartate Receptor Antagonist and Monoamine Oxidase–A Inhibitor, Attenuates Secondary Hyperalgesia in a Human Pain Model
  159. Pathophysiology of Alzheimer's Disease
  160. β-Amyloid Therapeutic Strategies for Alzheimer's Disease
  161. Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β-Amyloid1-42Secretion
  162. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects
  163. Mechanistic Pharmacokinetic and Pharmacodynamic Modeling of CHF3381 (2-[(2,3-Dihydro-1H-inden-2-yl)amino]acetamide Monohydrochloride), a Novel N-Methyl-d-aspartate Antagonist and Monoamine Oxidase-A Inhibitor in Healthy Subjects
  164. High Throughput Screening of β-Amyloid Secretion Inhibitors Using Homogenous Time-Resolved Fluorescence
  165. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer’s disease
  166. P4-342 High throughput screening of β-amyloid secretion inhibitors using homogenous time-resolved fluorescence
  167. O3-06-05 New flurbiprofen analogues, devoid of cyclooxygenase activity, selectively lower β-amyloid1–42 secretion
  168. Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice
  169. Safety, Pharmacokinetics, and Pharmacodynamics of CHF 3381, a Novel N-Methyl-D-Aspartate Antagonist, after Single Oral Doses in Healthy Subjects
  170. The protective effect of ganstigmine against amyloid beta25–35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition
  171. Perspectives on the Pharmacological Treatment of Dementia
  172. ?-Amyloid immunization approaches for Alzheimer's disease
  173. Toxicity of ?-amyloid vaccination in patients with Alzheimer's disease
  174. Pharmacodynamic-Tolerability Relationships of Cholinesterase Inhibitors for Alzheimer??s Disease
  175. Central acetylcholinesterase inhibition in Alzheimer patients
  176. Hemodynamic effects of MF 10058, a new cardioselective muscarinic M2 receptor antagonist, in conscious dogs
  177. A 6-Month, Double-Blind, Placebo-Controlled Trial of Eptastigmine in Alzheimer’s Disease
  178. Synthesis of New Cardioselective M2 Muscarinic Receptor Antagonists.
  179. PHARMACODYNAMICS OF A LONG ACTING DEPOT PREPARATION OF AVORELIN IN PATIENTS WITH PROSTATE CANCER
  180. Suicide in Two Patients with a Diagnosis of Probable Alzheimer Disease
  181. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease
  182. Two-Year Treatment of Alzheimer’s Disease with Eptastigmine
  183. Acetylcholinesterase assay may predict cognitive response of Alzheimer patients to eptastigmine treatment
  184. A 25-Week Placebo-Controlled Study of Eptastigmine in Patients with Alzheimer Disease
  185. Cardiac Autonomic Dysfunction in Patients with Alzheimer Disease: Possible Pathogenetic Mechanisms
  186. Maximum Tolerated Dose and Pharmacodynamics of Eptastigmine in Elderly Healthy Volunteers
  187. Effect of food on the absorption of eptastigmine
  188. Lack of effect of hexarelin on TRH-induced TSH response in normal adult man
  189. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis
  190. Acute administration of hexarelin stimulates GH secretion during day and night in normal men
  191. Population pharmacokinetics of rufloxacin in patients with acute exacerbations of chronic bronchitis
  192. Eptastigmine: A Cholinergic Approach to the Treatment of Alzheimer’s Disease
  193. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease*
  194. Pharmacodynamic monitoring of eptastigmine in capillary blood
  195. Effects of Hexarelin on Growth Hormone Secretion in Short Normal Children, in Obese Children, and in Subjects with Growth Hormone Deficiency
  196. The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency.
  197. The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency
  198. Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess
  199. A Patient-Side Technique for Real-Time Measurement of Acetylcholinesterase Activity During Monitoring of Eptastigmine Treatment
  200. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty.
  201. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty
  202. Relationship Between Pharmacokinetics and Pharmacodynamics of Eptastigmine in Young Healthy Volunteers
  203. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.
  204. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects
  205. Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly
  206. Hexarelin, a potent GHRP analogue: Interactions with GHRH and clonidine in young and aged dogs
  207. Mechanism of Action of Hexarelin and GHRP-6: Analysis of the Involvement of GHRH and Somatostatin in the Rat
  208. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man
  209. Modulation of Growth Hormone-Releasing Activity of Hexarelin in Man
  210. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects
  211. Distension-stimulated propagated contractions in human colon
  212. Growth hormone-releasing activity of hexarelin in humans
  213. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.
  214. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man
  215. A Pharmacodynamic Strategy to Optimize the Clinical Response to Eptastigmine (MF-201)
  216. Biliary excretion of rufloxacin in humans.
  217. Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects
  218. Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin.
  219. Multiple-dose pharmacokinetics of rufloxacin in patients with cirrhosis
  220. Prolonged Effects of Cholinesterase Inhibition with Eptastigmine on the Cerebral Blood Flow-Metabolism Ratio of Normal Rats
  221. Impaired colonic motor response to cholinergic stimulation in patients with severe chronic idiopathic (slow transit type) constipation
  222. Rapid potentiometric determination of cholinesterases in plasma and red cells: Application to eptastigmine monitoring
  223. Pharmacokinetics of rufloxacin in patients with impaired renal function.
  224. The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure.
  225. Pharmacokinetics of intramuscular dermatan sulfate (MF701) in patients with hip fracture
  226. Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases
  227. Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs
  228. The penetration of rufloxacin into sites of potential infection in the respiratory tract
  229. Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers.
  230. Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections
  231. Gallbladder hypokinesia and normal gastric emptying of liquids in patients with dyspeptic symptoms
  232. Steady-State Pharmacokinetics of Rufloxacin in Elderly Patients with Lower Respiratory Tract Infections
  233. 059 Preliminary data on heptastigmine monitoring
  234. High performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites N-desmethylrufloxacin and rufloxacinsulfoxide in plasma and urine of humans
  235. High-performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites, N-desmethylrufloxacin and rufloxacinsulfoxide, in urine of Rhesus monkey Macaca mulatta
  236. Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects
  237. Kinetics of cholinesterase inhibition by eptastigmine in man
  238. Edrophonium chloride for testing colonic contractile activity in man
  239. Efficiency of different criteria for selecting pharmacokinetic multiexponential equations
  240. Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers.
  241. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent
  242. Pharmacokinetics of Rufloxacin in Healthy Volunteers after Repeated Oral Doses
  243. Effects of cimetropium bromide on gallbladder contraction in response to oral and intraduodenal olive oil
  244. Inhibition of acetylcholinestense and butyrylcholinesterase after oral administration of heptastigmine in healthy volunteers
  245. Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial.
  246. Comparative Study of the Effects of Cimetropium Bromide and Atropine on Human Esophageal Motor Functions
  247. Inhibition of caerulein-induced gall bladder emptying by cimetropium bromide in humans
  248. Efficacy of cimetropium bromide as pre-medication for double-contrast barium enema
  249. Pharmacokinetics of mifentidine after single and multiple oral administration to healthy volunteers.
  250. A New Criterion for Selection of Pharmacokinetic Multiexponential Equations
  251. Colonic mass movements in idiopathic chronic constipation.
  252. Effect of mifentidine on peptone meal-stimulated gastric acid secretion and plasma gastrin levels in duodenal ulcer patients
  253. Gastric Acid and Pepsin Secretion after Single Oral Doses of Mifentidine in Healthy Subjects
  254. Manometric Evaluation of Cimetropium Bromide Activity in Patients with the Nutcracker Oesophagus
  255. Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome
  256. Safety and pharmacokinetics of mifentidine after increasing oral doses in healthy subjects
  257. Action of mifentidine on the secretory response to sham feeding and pentagastrin and on serum gastrin in duodenal ulcer patients
  258. Transverse and Sigmoid Colon Motility in Healthy Humans: Effects of Eating and of Cimetropium Bromide
  259. Urinary excretion of cimetropium bromide after multiple oral doses
  260. Discontinuous Oral Absorption of Cimetropium Bromide, a New Antispasmodic Drug
  261. Cimetropium bromide as a relaxant for the radiological examination of the stomach and duodenum
  262. Effects of Pirenzepine and Atropine on Gastroduodenal Motor Patterns in Duodenal Ulcer Patients
  263. The Use of Cimetropii Bromidum as Premedication for Endoscopy of the Upper Gastro-Intestinal Tract: A Double-Blind Controlled Clinical Trial